search
Back to results

HTX-011 in Spinal Surgery

Primary Purpose

Post-Operative Pain, Lumbar Laminectomy

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Bupivacaine HCI without epinephrine
HTX-011
Luer Lock Applicator
Sponsored by
Heron Therapeutics
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Post-Operative Pain focused on measuring postoperative pain, local anesthetic, lumbar laminectomy, lumbar decompression

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Is scheduled to undergo an open 1-3 level lumbar decompression surgery with or without fixation under general anesthesia.
  • Females are eligible only if not pregnant, not lactating, not planning to become pregnant during the study.

Exclusion Criteria:

  • Has a contraindication of a known or suspected history of hypersensitivity or clinically significant idiosyncratic reaction to required study medications.
  • Has a history of severe allergic reaction due to aspirin or other NSAIDs, or known history of severe gastrointestinal adverse reactions associated with NSAID use.
  • Has functioning intrathecal drug pump or spinal cord stimulator.
  • Has a history of spinal nerve ablation within 6 months of Screening (Part B only).
  • Opioid use for most days within the last 3 months.
  • Has initiated treatment with selective serotonin reuptake inhibitors (SSRIs), selective norepinephrine reuptake inhibitors (SNRIs), gabapentin, pregabalin, or duloxetine within 1 month prior to the scheduled surgery.
  • Received an investigational product or device in a clinical trial within 30 days or within 5 elimination half-lives.
  • Has a history of clinically significant cardiac abnormality, coronary artery bypass graft surgery within 12 months, or suspected coagulopathy or uncontrolled anticoagulation.
  • Has impaired balance and is at risk of falling.
  • Is currently undergoing treatment for hepatitis B, hepatitis C, or HIV.
  • Has undergone 3 or more surgeries within 12 months.
  • Has a known history of glucose-6-phosphate dehydrogenase deficiency.
  • Has History of liver cirrhosis, having an aspartate aminotransferase >3 × the upper limit of normal (ULN), or having an alanine aminotransferase >3 × ULN.

Sites / Locations

  • Arizona Research Center
  • Lotus Clinical Research, LLC
  • Kansas Spine and Specialty Hospital
  • Spine Institute of Louisiana
  • Overlook Medical Center
  • M3 Emerging Medical Research, LLC
  • The Ohio State University Wexner Medical Center - University Hospital
  • Austin Neurosurgeons
  • First Surgical Hospital
  • Houston Heights Hospital
  • South Texas Spine & Surgical Center
  • JBR Clinical Research

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Experimental

Arm Label

Cohort 1: Bupivacaine HCl

Cohort 2: HTX-011

Cohort 3: HTX-011

Arm Description

Bupivacaine HCl without epinephrine, via injection into the surgical site.

HTX-011 (bupivacaine/meloxicam) via application into the surgical site.

HTX-011 (bupivacaine/meloxicam) via application into the surgical site.

Outcomes

Primary Outcome Measures

Incidence of Serious Adverse Events

Secondary Outcome Measures

Maximum Observed Plasma Concentration (Cmax)
Time of occurrence of maximum concentration (Tmax)
Area under the concentration-time curve from Time 0 to the time of last quantitative concentration (AUClast)
Area under the concentration-time curve from Time 0 extrapolated to infinity (AUCinf)
Apparent terminal half-life (t½)

Full Information

First Posted
May 27, 2021
Last Updated
June 5, 2023
Sponsor
Heron Therapeutics
search

1. Study Identification

Unique Protocol Identification Number
NCT04911062
Brief Title
HTX-011 in Spinal Surgery
Official Title
A Phase 2, Two-Part, Multicenter Study of HTX-011 in Spinal Surgery
Study Type
Interventional

2. Study Status

Record Verification Date
June 2023
Overall Recruitment Status
Completed
Study Start Date
April 7, 2022 (Actual)
Primary Completion Date
July 29, 2022 (Actual)
Study Completion Date
August 26, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Heron Therapeutics

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a Phase 2, multicenter study in subjects undergoing an open lumbar decompression surgery.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Post-Operative Pain, Lumbar Laminectomy
Keywords
postoperative pain, local anesthetic, lumbar laminectomy, lumbar decompression

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Sequential Assignment
Masking
None (Open Label)
Masking Description
Optional Part B will be randomized, blinded, active-controlled.
Allocation
Non-Randomized
Enrollment
32 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Cohort 1: Bupivacaine HCl
Arm Type
Experimental
Arm Description
Bupivacaine HCl without epinephrine, via injection into the surgical site.
Arm Title
Cohort 2: HTX-011
Arm Type
Experimental
Arm Description
HTX-011 (bupivacaine/meloxicam) via application into the surgical site.
Arm Title
Cohort 3: HTX-011
Arm Type
Experimental
Arm Description
HTX-011 (bupivacaine/meloxicam) via application into the surgical site.
Intervention Type
Drug
Intervention Name(s)
Bupivacaine HCI without epinephrine
Intervention Description
100 mg administered via injection into the surgical site.
Intervention Type
Drug
Intervention Name(s)
HTX-011
Intervention Description
HTX-011 (bupivacaine/meloxicam) dose up to 200 mg/6 mg administered via application into the surgical site.
Intervention Type
Device
Intervention Name(s)
Luer Lock Applicator
Intervention Description
Applicator for instillation.
Primary Outcome Measure Information:
Title
Incidence of Serious Adverse Events
Time Frame
From the time the subject signs the ICF through the Day 29 Visit
Secondary Outcome Measure Information:
Title
Maximum Observed Plasma Concentration (Cmax)
Time Frame
Baseline through 120 hours
Title
Time of occurrence of maximum concentration (Tmax)
Time Frame
Baseline through 120 hours
Title
Area under the concentration-time curve from Time 0 to the time of last quantitative concentration (AUClast)
Time Frame
Baseline through 120 hours
Title
Area under the concentration-time curve from Time 0 extrapolated to infinity (AUCinf)
Time Frame
Baseline through 120 hours
Title
Apparent terminal half-life (t½)
Time Frame
Baseline through 120 hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Is scheduled to undergo an open 1-3 level lumbar decompression surgery with or without fixation under general anesthesia. Females are eligible only if not pregnant, not lactating, not planning to become pregnant during the study. Exclusion Criteria: Has a contraindication of a known or suspected history of hypersensitivity or clinically significant idiosyncratic reaction to required study medications. Has a history of severe allergic reaction due to aspirin or other NSAIDs, or known history of severe gastrointestinal adverse reactions associated with NSAID use. Has functioning intrathecal drug pump or spinal cord stimulator. Opioid use for most days within the last 3 months. Has initiated treatment with selective serotonin reuptake inhibitors (SSRIs), selective norepinephrine reuptake inhibitors (SNRIs), gabapentin, pregabalin, or duloxetine within 1 month prior to the scheduled surgery. Received an investigational product or device in a clinical trial within 30 days or within 5 elimination half-lives. Has a history of clinically significant cardiac abnormality, coronary artery bypass graft surgery within 12 months, or suspected coagulopathy or uncontrolled anticoagulation. Has impaired balance and is at risk of falling. Is currently undergoing treatment for hepatitis B, hepatitis C, or HIV. Has undergone 3 or more surgeries within 12 months. Has a known history of glucose-6-phosphate dehydrogenase deficiency. Has History of liver cirrhosis, having an aspartate aminotransferase >3 × the upper limit of normal (ULN), or having an alanine aminotransferase >3 × ULN.
Facility Information:
Facility Name
Arizona Research Center
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85053
Country
United States
Facility Name
Lotus Clinical Research, LLC
City
Pasadena
State/Province
California
ZIP/Postal Code
91105
Country
United States
Facility Name
Kansas Spine and Specialty Hospital
City
Wichita
State/Province
Kansas
ZIP/Postal Code
67226
Country
United States
Facility Name
Spine Institute of Louisiana
City
Shreveport
State/Province
Louisiana
ZIP/Postal Code
71101
Country
United States
Facility Name
Overlook Medical Center
City
Summit
State/Province
New Jersey
ZIP/Postal Code
07901
Country
United States
Facility Name
M3 Emerging Medical Research, LLC
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27704
Country
United States
Facility Name
The Ohio State University Wexner Medical Center - University Hospital
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43210
Country
United States
Facility Name
Austin Neurosurgeons
City
Austin
State/Province
Texas
ZIP/Postal Code
78746
Country
United States
Facility Name
First Surgical Hospital
City
Bellaire
State/Province
Texas
ZIP/Postal Code
77401
Country
United States
Facility Name
Houston Heights Hospital
City
Houston
State/Province
Texas
ZIP/Postal Code
77008
Country
United States
Facility Name
South Texas Spine & Surgical Center
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78258
Country
United States
Facility Name
JBR Clinical Research
City
Salt Lake City
State/Province
Utah
ZIP/Postal Code
84107
Country
United States

12. IPD Sharing Statement

Learn more about this trial

HTX-011 in Spinal Surgery

We'll reach out to this number within 24 hrs